Prolonged remission of disseminated atypical adenomatous hyperplasia under gefitinib

Research output: Contribution to journalArticlepeer-review


Atypical adenomatous hyperplasia (AAH) is a putative precursor of bronchioloalveolar carcinoma (BAC) and adenocarcinoma of the lung, developing from terminal respiratory unit cells. AAH and BAC lesions typically present as ground-glass opacities at spiral chest computed tomography. Epidermal growth factor receptor polysomy/mutations, conferring higher sensitivity to Gefitinib, are frequent in BAC but less common in AAH. We describe an interesting case of disseminated AAH showing a sustained remission under Gefitinib therapy.

Original languageEnglish
Pages (from-to)266-267
Number of pages2
JournalJournal of Thoracic Oncology
Issue number2
Publication statusPublished - Feb 2009


  • AAH
  • BAC
  • CT screening
  • FISH
  • Gefitinib

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Medicine(all)


Dive into the research topics of 'Prolonged remission of disseminated atypical adenomatous hyperplasia under gefitinib'. Together they form a unique fingerprint.

Cite this